Abstract
Lung cancer is the leading cancer killer in the USA. Proton beam therapy offers both unique promise and special dosimetric challenges compared with photons in treating lung cancer. It is essential to account for density changes along the path of the proton beam during treatment. Simulation with 4D CT scanning can help account for tumor motion due to breathing. Proton beam therapy is being evaluated both for stage 1 and locally and/or regionally advanced stage 3 non-small cell lung cancer as a means to improve local control and shield critical normal tissues within the thorax from the harmful effects of radiation. For medically inoperable stage 1 disease, stereotactic hypofractionated body proton beam therapy is being evaluated. For unresectable stage 3 disease, combined chemotherapy with proton beam therapy is being studied. Selected dosimetric and clinical studies are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi:10.3322/caac.20138 [Epub January 4, 2012].
Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol. 2007;25(35):5557–61.
Dillman RO, Herndon J, Seagren SL, Eaton Jr WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88(17):1210–5.
Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning for lung tumors. Int J Radiat Oncol Biol Phys. 2006;64(5):1589–95.
Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys. 2001;49(5):1429–38.
Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small-cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty. Int J Radiat Oncol Biol Phys. 2012;83(1):354–61.
Britton KR, Starkschall G, Tucker SL, et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007;68(4):1036–46.
Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.
Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1350–7.
Grutters JPC, Kessels AGH, Pijls-Johannesma M, et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010;95:32–40.
Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 2011;117(20):4707–13.
Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012;7(1):165–76.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yajnik, S. (2013). Proton Beam Therapy for Lung Cancer. In: Proton Beam Therapy. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5298-0_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5298-0_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5297-3
Online ISBN: 978-1-4614-5298-0
eBook Packages: MedicineMedicine (R0)